Journal of Clinical Epidemiology
Volume 63, Issue 4 , Pages 347-349 , April 2010

A probiotics trial on trial: the problem of timely detection of adverse advents in therapeutic trials

  • Raimond W.M. Giard

      Affiliations

    • Department of Clinical Pathology, Maasstad Ziekenhuis, Rotterdam, The Netherlands
    • Rotterdam Institute of Private Law, Department of Civil Law, Erasmus School of Law, Erasmus University Rotterdam, Rotterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Department of Clinical Pathology, Maasstad Ziekenhuis, PO Box 9119, 3007 AC Rotterdam, The Netherlands. Tel.: +31-0-291-15-16; fax: +31-0-291-1035.

,Accepted 15 December 2008.

References 

  1. Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, et al. Dutch Acute Pancreatitis Study Group. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:651–659
  2. Gill RD. Statistics, ethics, and probiotica. Statistica Neerlandica. 2009;63:1–12Available at: http://arxiv.org/abs/0804.2522v1
  3. Dekker S. The field guide to understanding human error. Aldershot: Ashgate; 2006;
  4. Henriksen K, Kaplan H. Hindsight bias, outcome knowledge and adaptive learning. Qual Saf Health Care. 2003;12(Suppl 2):ii46–ii50
  5. Pocock SJ. Current controversies in data monitoring for clinical trials. Clin Trials. 2006;3:513–521
  6. Bassler D, Montori VM, Briel M, Glasziou P, Guyatt G. Early stopping of randomized clinical trials for overt efficacy is problematic. J Clin Epidemiol. 2008;61:241–246
  7. Berry DA. Bayesian clinical trials. Nat Rev Drug Discov. 2006;5:27–36
  8. Todd S, Whitehead A, Stallard N, Whitehead J. Interim analyses and sequential designs in phase III studies. Br J Clin Pharmacol. 2001;51:394–399
  9. Strech D, Tilburt J. Value judgments in the analysis and synthesis of evidence. J Clin Epidemiol. 2008;61:521–524
  10. Besselink MG, Timmerman HM, Buskens E, Nieuwenhuijs VB, Akkermans LM, Gooszen HG. Dutch Acute Pancreatitis Study Group. Probiotic prophylaxis in patients with predicted severe acute pancreatitis (PROPATRIA): design and rationale of a double-blind, placebo-controlled randomised multicenter trial [ISRCTN38327949]. BMC Surg. 2004;4:12
  11. Pocock SJ. The simplest statistical test: how to check for a difference between treatments. BMJ. 2006;332:1256–1258
  12. Feinstein AR. P-Values and confidence intervals: two sides of the same unsatisfactory coin. J Clin Epidemiol. 1998;51:355–360
  13. Chalmers I. Confronting therapeutic ignorance. BMJ. 2008;337:246–247
  14. McCartney . Leaping to conclusions. BMJ. 2008;336:1213–1214
  15. Mello MM, Studdert DM, Brennan TA. The rise of litigation in human subjects research. Ann Intern Med. 2003;139:40–45
  16. Edwards W. How to make good decisions. Acta Psychol. 1984;56:5–27
  17. DeMets DL, Fleming TR, Rockhold F, Massie B, Merchant T, Meisel A, et al. Liability issues for data monitoring committee members. Clin Trials. 2004;1:525–531
  18. Kpozèhouen A, Alioum A, Anglaret X, Van de Perre P, Chêne G, Salamon R. Use of a Bayesian approach to decide when to stop a therapeutic trial: the case of a chemoprophylaxis trial in human immunodeficiency virus infection. Am J Epidemiol. 2005;161:595–603
  19. Howard G, Coffey CS, Cutter GR. Is Bayesian analysis ready for use in phase III randomized clinical trials? Beware the sound of the sirens. Stroke. 2005;36:6122–6123

PII: S0895-4356(09)00210-8

doi: 10.1016/j.jclinepi.2008.12.012

Journal of Clinical Epidemiology
Volume 63, Issue 4 , Pages 347-349 , April 2010

Article Tools